Translational potential of a novel osteoclast inhibitor, eliglustat, in myeloma bone disease
<p>Multiple myeloma is a fatal haematological malignancy, in which the majority of patients either present with or develop a destructive and debilitating osteolytic bone disease. The bone disease is characterised by an increase in osteoclastogenesis and by osteoblast suppression. Current trea...
Հիմնական հեղինակ: | |
---|---|
Այլ հեղինակներ: | |
Ձևաչափ: | Թեզիս |
Լեզու: | English |
Հրապարակվել է: |
2019
|
Խորագրեր: |